MapLight Therapeutics——计划启动一项额外的注册性试验,并在二期临床结束时与美国食品药品监督管理局(FDA)展开对接。
MapLight Therapeutics——计划启动一项额外的注册性试验,并在二期临床结束时与美国食品药品监督管理局(FDA)展开对接。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.